Survival Nomograms after Curative Neoadjuvant Chemotherapy and Radical Surgery for Stage IB2-IIIB Cervical Cancer.
- Author:
Claudia MARCHETTI
1
;
Francesca DE FELICE
;
Anna DI PINTO
;
Alessia ROMITO
;
Angela MUSELLA
;
Innocenza PALAIA
;
Marco MONTI
;
Vincenzo TOMBOLIN
;
Ludovico MUZII
;
PierLuigi BENEDETTI PANICI
Author Information
- Publication Type:Original Article
- Keywords: Nomograms; Locally advanced disease; Uterine cervical neoplasms; Neoadjuvant chemotherapy; Radical surgery; Clinical outcomes; Survival; Recurrence
- MeSH: Body Mass Index; Calibration; Chemoradiotherapy; Disease-Free Survival; Drug Therapy*; Follow-Up Studies; Humans; Lymph Nodes; Nomograms*; Recurrence; Uterine Cervical Neoplasms*
- From:Cancer Research and Treatment 2018;50(3):768-776
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: The purpose of this study was to develop nomograms for predicting the probability of overall survival (OS) and progression-free survival (PFS) in locally advanced cervical cancer treated with neoadjuvant chemotherapy and radical surgery. MATERIALS AND METHODS: Nomograms to predict the 5-year OS rates and the 2-year PFS rates were constructed. Calibration plots were constructed, and concordance indices were calculated. Evaluated variableswere body mass index, age, tumor size, tumor histology, grading, lymphovascular space invasion, positive parametria, and positive lymph nodes. RESULTS: In total 245 patients with locally advanced cervical cancer who underwent neoadjuvant chemotherapy and radical surgery were included for the construction of the nomogram. The 5-year OS and PFS were 72.6% and 66%, respectively. Tumor size, grading, and parametria status affected the rate of OS, whereas tumor size and positive parametria were the main independent PFS prognostic factors. CONCLUSION: We constructed a nomogram based on clinicopathological features in order to predict 2-year PFS and 5-year OS in locally advanced cervical cancer primarily treated with neoadjuvant chemotherapy followed by radical surgery. This tool might be particularly helpful for assisting in the follow-up of cervical cancer patients who have not undergone concurrent chemoradiotherapy.
